Mereo BioPharma (MREO) Change in Accured Expenses (2023 - 2026)

Mereo BioPharma (MREO) has reported Change in Accured Expenses for 4 consecutive years, with $229000.0 the latest figure, recorded in Q1 2026.

• Quarterly Change in Accured Expenses rose 116.47% year-over-year to $229000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$775000.0 (down 317.09% YoY) and the FY2025 annual result came in at -$2.4 million, down 100.84% from the prior year.
• Change in Accured Expenses climbed to $229000.0 in Q1 2026 per MREO's latest filing, from -$2.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for MREO reached as high as $4.2 million in Q2 2023 and fell as low as -$3.1 million in Q1 2023.
• A 4-year average of -$312846.2 and a median of -$706000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses sank 442.47% — and 2026, when it surged 116.47%.
• Year by year, Change in Accured Expenses stood at -$1.7 million in 2023, then jumped by 58.79% to -$706000.0 in 2024, then plunged by 220.25% to -$2.3 million in 2025, then surged by 110.13% to $229000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $229000.0, -$2.3 million, and -$673000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.